| Date Filed | Type | Description |
| 07/27/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/07/2023 |
SC 13D
| INGALLS & SNYDER LLC reports a 4.2% stake in ImmunoPrecise Antibodies Ltd. |
| 05/09/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 01/31/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 10/21/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/11/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/09/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/11/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/04/2022 |
SC 13G
| INGALLS & SNYDER LLC reports a 8.1% stake in APPLIED ENERGETICS, INC |
| 02/04/2022 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 14% stake in STRATUS PROPERTIES, INC. |
| 02/04/2022 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 7.1% stake in OMEROS CORPORATION |
| 02/04/2022 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 5.7% stake in CORCEPT THERAPEUTICS, INC. |
| 11/22/2021 |
SC 13D/A
| INGALLS & SNYDER LLC reports a 4.8% stake in Inuvo, Inc. |
| 10/27/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/03/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 04/21/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/09/2021 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 15.1% stake in STRATUS PROPERTIES, INC. |
| 02/09/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2021 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 6.5% stake in CORCEPT THERAPEUTICS, INC. |
| 02/09/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2021 |
SC 13D/A
| INGALLS & SNYDER LLC reports a 4.5% stake in Inuvo, Inc. |
| 01/27/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 10/21/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/31/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 04/22/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/28/2020 |
SC 13D/A
| INGALLS & SNYDER LLC reports a 11% stake in Inuvo, Inc. |
| 02/07/2020 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 7.2% stake in CORCEPT THERAPEUTICS, INC. |
| 02/07/2020 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 9.4% stake in OMEROS CORPORATION |
| 02/07/2020 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 15.6% stake in STRATUS PROPERTIES, INC. |
| 02/07/2020 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 3.8% stake in AMERICAS GOLD AND SILVER CORPORATION |
| 02/07/2020 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 4.8% stake in MOSYS, INC. |
| 02/07/2020 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 13.5% stake in MOSYS. INC. |
| 01/23/2020 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 4% stake in DURECT CORPORATION |
| 01/23/2020 |
SC 13G/A
| INGALLS & SNYDER LLC reports a 6.1% stake in CONCERT PHARMACEUTICALS, INC. |
|